Acrivon Therapeutics Statistics
Total Valuation
ACRV has a market cap or net worth of $68.57 million. The enterprise value is -$60.87 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRV has 31.46 million shares outstanding. The number of shares has increased by 48.59% in one year.
| Current Share Class | 31.46M |
| Shares Outstanding | 31.46M |
| Shares Change (YoY) | +48.59% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 7.67% |
| Owned by Institutions (%) | 29.55% |
| Float | 16.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.31, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.31 |
| Quick Ratio | 10.23 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -47.87% and return on invested capital (ROIC) is -32.19%.
| Return on Equity (ROE) | -47.87% |
| Return on Assets (ROA) | -30.32% |
| Return on Invested Capital (ROIC) | -32.19% |
| Return on Capital Employed (ROCE) | -65.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.10M |
| Employee Count | 78 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.66% in the last 52 weeks. The beta is 1.82, so ACRV's price volatility has been higher than the market average.
| Beta (5Y) | 1.82 |
| 52-Week Price Change | -72.66% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 2.41 |
| Relative Strength Index (RSI) | 61.99 |
| Average Volume (20 Days) | 1,039,273 |
Short Selling Information
The latest short interest is 1.64 million, so 5.20% of the outstanding shares have been sold short.
| Short Interest | 1.64M |
| Short Previous Month | 1.15M |
| Short % of Shares Out | 5.20% |
| Short % of Float | 9.80% |
| Short Ratio (days to cover) | 3.23 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -94.41M |
| Pretax Income | -85.96M |
| Net Income | -85.96M |
| EBITDA | -93.21M |
| EBIT | -94.41M |
| Earnings Per Share (EPS) | -$2.24 |
Full Income Statement Balance Sheet
The company has $137.42 million in cash and $3.26 million in debt, giving a net cash position of $134.16 million or $4.27 per share.
| Cash & Cash Equivalents | 137.42M |
| Total Debt | 3.26M |
| Net Cash | 134.16M |
| Net Cash Per Share | $4.27 |
| Equity (Book Value) | 143.04M |
| Book Value Per Share | 4.55 |
| Working Capital | 124.98M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$70.83 million and capital expenditures -$2.37 million, giving a free cash flow of -$73.20 million.
| Operating Cash Flow | -70.83M |
| Capital Expenditures | -2.37M |
| Free Cash Flow | -73.20M |
| FCF Per Share | -$2.33 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.59% |
| Shareholder Yield | -48.59% |
| Earnings Yield | -117.28% |
| FCF Yield | -99.87% |
Analyst Forecast
The average price target for ACRV is $17.75, which is 714.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.75 |
| Price Target Difference | 714.22% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -4.29% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |